Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients

Transplantation

Volumn 66, Issue 12, 1998, Pages 1604-1611

  McDiarmid, Sue V ^a   Jordan, Stan ^b   Lee, Geoffrey S ^a   Toyoda, Meiko ^b   Goss, John A ^a   Vargas, Jorge H ^a   Martín, Martín G ^a   Bahar, Ron ^a   Maxfield, Anne L ^a   Ament, Marvin E ^a   Busuttil, Ronald W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; PREDNISONE; TACROLIMUS;

ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTIOUS MONONUCLEOSIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS TITRATION;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; GANCICLOVIR; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; INFANT, NEWBORN; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; TUMOR VIRUS INFECTIONS;

EID: 0032573721     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00006     Document Type: Article

References (58)

1. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996; 62: 370.
2. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101.
3. Penn I. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc 1994; 26: 2763.
4. Malatack JJ, Gartner JC, Urbach AH, Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991; 118: 667.
5. Younes B, McDiarmid S, Martin M, et al. The effect of immunosuppression on post transplant lympho-proliferative disease in pediatric liver transplant patients. Transplantation 1998 (in press).
6. Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 1992; 54: 250.
7. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993; 81: 1393.
8. Sokol EM, Caragiozoglou T, Lamy M, Reding R, Otte J. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 1394.
9. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719.
10. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
11. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214.
12. Reyes J, Green M, Bueno J, et al. Epstein Barr virus associated posttransplant lymphoproliferative disease after intestinal transplantation. Transplant Proc 1996; 28: 2768.
13. Putnam P, Reyes J, Kocoshis S, et al. Gastrointestinal posttransplant lymphoproliferative disease in children. Transplant Proc 1996; 28: 2777.
14. Nalesnik MA, Lacker J, Jaffe R, et al. Experience with post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 1992; 6: 249.
15. Cacciarelli TV, Green M, Jaffe R, Mieles L, Fung JJ, Reyes J. Management of post-transplant lymphoproliferative disorder (PTLD) in pediatric liver transplant recipients receiving primary tacrolimus (FK 506) therapy [Abstract]. Liver Transplant Surg 1997; 3: C-47.
16. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473.
17. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994; 57: 93.
18. McDiarmid SV, Wallace P, Vargas J, Ament ME, Busuttil RW. The treatment of intractable rejection with FK506 in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 1995; 20: 291.
19. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240.
20. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
21. Rustgi VK. Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders. Liver Transplant Surg 1995; 1: 100.
22. Nalesnik MA, Randhawa P, Demetris AJ, Casavilla A, Fung JJ, Locker J. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993; 72: 2568.
23. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors. N Engl J Med 1995; 332: 19.
24. McDiarmid S, Goss J, Seu P, et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. Transplant Proc 1998; 30: 1397.
25. Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990; 14: 538.
26. Markin RS. Manifestations of Epstein-Barr virus-associated disorders in liver. Liver 1994; 14: 1.
27. Starzl TE, Nalesnik M, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
28. Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 1984; 50: 50.
29. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721.
30. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993; 7: 467.
31. Breinig MK, Zitelli B, Starzl TE, Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987; 156: 273.
32. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
33. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327: 1710.
34. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98.
35. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612.
36. Martinez OM, Villanueva JC, Lawrence-Miyasaki LS, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995; 59: 519.
37. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995; 60: 547.
38. Pedneault L, Katz BZ, Miller G. Detection of Epstein-Barr virus in the brain by the polymerase chain reaction. Ann Neurol 1992; 32: 184.
39. Lubin MB, Elashoff JD, Wang SJ, Rotter JI, Toyoda H. Precise gene dosage determination by polymerase chain reaction: theory, methodology, and statistical approach. Mol Cell Probes 1991; 5: 307.
40. Cao S, Cox K, Esquivel CO, et al. PTLD and gastrointestinal manifestations of EBV infection in children following liver transplantation [Abstract] American Society of Transplant Physicians, May 26-30, 1996.
41. Nalesnik MA. Involvement of the gastrointestinal tract by Epstein-Barr virus-associated posttransplant lymphoproliferative disorders. Am J Surg Pathol 1990; 14 (Suppl 1): 92.
42. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Transplantation 1995; 59: 530.
43. Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK 506 in pediatric patients. Transplant Proc 1993; 25: 619.
44. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61: 1188.
45. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61: 247.
46. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972.
47. Green M, Reyes J, Jabbour N, et al. Use of quantitative PCR to predict onset of Epstein-Barr viral infection and post-transplant lymphoproliferative disease after intestinal transplantation in children. Transplant Proc 1996; 28: 2759.
48. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715.
49. Lamy M, Favart Am, Cornu C, et al. Epstein-Barr virus infection in 59 orthotopic liver transplant patients. Med Microbiol Immunol 1990; 179: 137.
50. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995; 59: 135.
51. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
52. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
53. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997; 64: 1614.
54. Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transplant 1997; 11: 613.
55. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462.
56. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 1981; 41: 4222.
57. Seiden MV, Sklar J. Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol Oncol Clin North Am 1993; 7: 447.
58. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200.